Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs

Core Viewpoint - Quantum BioPharma Ltd. has engaged Enterprise Canada Inc. and Empire Market Ventures, LLC to enhance its public relations and investor awareness efforts across key markets [1][2][6] Group 1: Engagement of Agencies - The decision to retain the services of Enterprise and Empire was made after a thorough review of available capital [2] - Enterprise has been engaged for an indefinite period starting December 18, 2024, with a structured payment plan totaling C$10,000 for Phase 1 and a monthly retainer of C$5,000 thereafter [3][4] - Empire has been contracted for three months starting February 7, 2025, with a total fee of US$25,000 [5][6] Group 2: Services Provided - Enterprise will assist with public relations strategy, including narrative development, key messaging, and media relationships [4] - Empire will provide investor awareness services, including access to exclusive mailing lists and content creation aimed at increasing investor engagement [6] Group 3: Product Updates - Quantum BioPharma's product unbuzzd™ is a rapid alcohol detoxification beverage, with a ready-to-drink formulation expected to be available in Q1 2025 [7][9] - rekvry™ is designed for alcohol misuse treatment, targeting emergency and hospital settings to reduce healthcare costs [7][9] - LUCID-21-302 is a new chemical entity aimed at treating demyelinating diseases, with an initial focus on multiple sclerosis [8][9] Group 4: Company Overview - Quantum BioPharma is focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse [10] - The company retains a 25.71$250 million [11]